Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock?
10:20am, Friday, 09'th Jan 2026
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 17.3% over the past six months compared with the industry's growth of 23.4%.
Cerity Partners LLC Has $42.50 Million Holdings in Bristol Myers Squibb Company $BMY
05:04am, Thursday, 08'th Jan 2026
Cerity Partners LLC grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
CX Institutional Has $7.48 Million Stock Position in Bristol Myers Squibb Company $BMY
05:04am, Thursday, 08'th Jan 2026
CX Institutional grew its position in Bristol Myers Squibb Company (NYSE: BMY) by 9.2% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange
3 Drug Stocks to Buy at a Discount
04:00pm, Wednesday, 07'th Jan 2026
Eli Lilly's GLP-1 weight loss drug is leading investors to award it a massive P/E ratio of 53. That's far higher than the pharmaceutical sector's average P/E ratio of about 30.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Wednesday, 07'th Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again
01:10pm, Tuesday, 06'th Jan 2026
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:56am, Tuesday, 06'th Jan 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Gateway Investment Advisers LLC Has $5.12 Million Stake in Bristol Myers Squibb Company $BMY
07:56am, Monday, 05'th Jan 2026
Gateway Investment Advisers LLC raised its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 10.0% during the undefined quarter, according to the company in its most recent 13F filing
Railway Pension Investments Ltd Purchases 40,300 Shares of Bristol Myers Squibb Company $BMY
07:18am, Monday, 05'th Jan 2026
Railway Pension Investments Ltd grew its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 3.7% in the undefined quarter, according to the company in its most recent disclosure with th
Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference
06:59am, Friday, 02'nd Jan 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference.
Generali Asset Management SPA SGR Reduces Holdings in Bristol Myers Squibb Company $BMY
04:42am, Friday, 02'nd Jan 2026
Generali Asset Management SPA SGR lowered its position in Bristol Myers Squibb Company (NYSE: BMY) by 16.5% in the undefined quarter, according to the company in its most recent filing with the SEC. T
Bristol Myers Squibb Company $BMY Shares Purchased by Cantor Fitzgerald Investment Advisors L.P.
05:24am, Thursday, 01'st Jan 2026
Cantor Fitzgerald Investment Advisors L.P. raised its holdings in Bristol Myers Squibb Company (NYSE: BMY) by 6.7% during the third quarter, according to the company in its most recent filing with the
2 Dividend Stocks to Scoop Up Without Hesitation Right Now
11:45am, Wednesday, 31'st Dec 2025
Great dividend payers can support and raise their payouts through the years. VICI Properties is a leading REIT with a vast portfolio of experience-oriented properties.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
10:01am, Wednesday, 31'st Dec 2025
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
08:35am, Wednesday, 31'st Dec 2025
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
